{"id":224790,"date":"2026-08-31T16:48:33","date_gmt":"2026-08-31T11:18:33","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/bajaj-finserv-healthcare-fund-direct-growth-review-2026\/"},"modified":"2026-09-16T09:10:11","modified_gmt":"2026-09-16T03:40:11","slug":"bajaj-finserv-healthcare-fund-direct-growth-review-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/bajaj-finserv-healthcare-fund-direct-growth-review-2026\/","title":{"rendered":"Bajaj Finserv Healthcare Fund Direct Growth Review 2026: NAV, Returns, Portfolio &#038; Should You Invest?"},"content":{"rendered":"<p><a href=\"https:\/\/univest.in\/mutual-funds\/bajaj-finserv-healthcare-fund-g-direct-plan\">Bajaj Finserv Healthcare Fund Direct Growth Plan<\/a> has a NAV of \u20b912.084 as of 15 Sep 2026 and an AUM of \u20b9405 Cr. Its 1-year, 3-year and 5-year returns are 20.48%, 0%, and 0% respectively, and it sits in the High Risk bucket. Our view is that the fund has shown a strong one-year run, but its short history means the longer track record is still too limited to judge the full cycle.<\/p>\n<p>The fund may suit investors who want healthcare exposure and can accept sharp swings. The portfolio is concentrated in a handful of large healthcare names, which can amplify both gains and drawdowns when the sector moves.<\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/bajaj-finserv-healthcare-fund-direct-growth-review-2026\/#Quick_facts\" title=\"Quick facts\">Quick facts<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/bajaj-finserv-healthcare-fund-direct-growth-review-2026\/#Performance\" title=\"Performance\">Performance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/bajaj-finserv-healthcare-fund-direct-growth-review-2026\/#Should_you_BUY_or_HOLD_Bajaj_Finserv_Healthcare\" title=\"Should you BUY or HOLD Bajaj Finserv Healthcare?\">Should you BUY or HOLD Bajaj Finserv Healthcare?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/bajaj-finserv-healthcare-fund-direct-growth-review-2026\/#Peer_comparison\" title=\"Peer comparison\">Peer comparison<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/bajaj-finserv-healthcare-fund-direct-growth-review-2026\/#Portfolio_where_your_money_goes\" title=\"Portfolio: where your money goes\">Portfolio: where your money goes<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/bajaj-finserv-healthcare-fund-direct-growth-review-2026\/#Who_should_invest\" title=\"Who should invest\">Who should invest<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/bajaj-finserv-healthcare-fund-direct-growth-review-2026\/#Tax_and_exit_load\" title=\"Tax and exit load\">Tax and exit load<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/bajaj-finserv-healthcare-fund-direct-growth-review-2026\/#Frequently_asked_questions\" title=\"Frequently asked questions\">Frequently asked questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/bajaj-finserv-healthcare-fund-direct-growth-review-2026\/#What_is_the_current_NAV_of_Bajaj_Finserv_Healthcare_Fund_Direct_Growth_Plan\" title=\"What is the current NAV of Bajaj Finserv Healthcare Fund Direct Growth Plan?\">What is the current NAV of Bajaj Finserv Healthcare Fund Direct Growth Plan?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/bajaj-finserv-healthcare-fund-direct-growth-review-2026\/#What_are_the_funds_1-year_3-year_and_5-year_returns\" title=\"What are the fund\u2019s 1-year, 3-year and 5-year returns?\">What are the fund\u2019s 1-year, 3-year and 5-year returns?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/bajaj-finserv-healthcare-fund-direct-growth-review-2026\/#How_has_the_fund_performed_against_the_benchmark\" title=\"How has the fund performed against the benchmark?\">How has the fund performed against the benchmark?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/bajaj-finserv-healthcare-fund-direct-growth-review-2026\/#How_does_it_compare_with_the_listed_peer_funds\" title=\"How does it compare with the listed peer funds?\">How does it compare with the listed peer funds?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/bajaj-finserv-healthcare-fund-direct-growth-review-2026\/#Is_there_a_minimum_SIP_amount\" title=\"Is there a minimum SIP amount?\">Is there a minimum SIP amount?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/bajaj-finserv-healthcare-fund-direct-growth-review-2026\/#What_are_the_risk_profile_portfolio_style_and_exit_load\" title=\"What are the risk profile, portfolio style and exit load?\">What are the risk profile, portfolio style and exit load?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/bajaj-finserv-healthcare-fund-direct-growth-review-2026\/#Bottom_line\" title=\"Bottom line\">Bottom line<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/bajaj-finserv-healthcare-fund-direct-growth-review-2026\/#Explore_mutual_funds_with_Univest\" title=\"Explore mutual funds with Univest\">Explore mutual funds with Univest<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/bajaj-finserv-healthcare-fund-direct-growth-review-2026\/#RIA_disclosure\" title=\"RIA disclosure\">RIA disclosure<\/a><\/li><\/ul><\/nav><\/div>\n<h2 style=\"font-weight:700\"><span class=\"ez-toc-section\" id=\"Quick_facts\"><\/span>Quick facts<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Particular<\/th>\n<th>Details<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>NAV<\/td>\n<td>\u20b912.084 as of 15 Sep 2026<\/td>\n<\/tr>\n<tr>\n<td>AUM<\/td>\n<td>\u20b9405 Cr<\/td>\n<\/tr>\n<tr>\n<td>Expense Ratio<\/td>\n<td>0.72%<\/td>\n<\/tr>\n<tr>\n<td>Launch Date<\/td>\n<td>27 Dec 2024<\/td>\n<\/tr>\n<tr>\n<td>Min SIP<\/td>\n<td>\u20b9500<\/td>\n<\/tr>\n<tr>\n<td>Risk Category<\/td>\n<td>High Risk<\/td>\n<\/tr>\n<tr>\n<td>Benchmark<\/td>\n<td>Nifty 50<\/td>\n<\/tr>\n<tr>\n<td>Fund Category<\/td>\n<td>Equity<\/td>\n<\/tr>\n<tr>\n<td>Exit Load<\/td>\n<td>1% on or before 3M, Nil after 3M<\/td>\n<\/tr>\n<tr>\n<td>Fund Managers<\/td>\n<td>Vinay Bafna, Bharat Hegde, Siddharth Chaudhary<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The fund is managed by Vinay Bafna, Bharat Hegde, and Siddharth Chaudhary.<\/p>\n<p class=\"mf-source-date\"><small>Source data date: as of 15 Sep 2026<\/small><\/p>\n<h2 style=\"font-weight:700\"><span class=\"ez-toc-section\" id=\"Performance\"><\/span>Performance<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Period<\/th>\n<th>Fund return<\/th>\n<th>Benchmark return<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1M<\/td>\n<td>0.22%<\/td>\n<td>-4.81%<\/td>\n<\/tr>\n<tr>\n<td>3M<\/td>\n<td>12.68%<\/td>\n<td>-3.63%<\/td>\n<\/tr>\n<tr>\n<td>1Y<\/td>\n<td>20.48%<\/td>\n<td>-8.27%<\/td>\n<\/tr>\n<tr>\n<td>3Y<\/td>\n<td>Data not available<\/td>\n<td>Data not available<\/td>\n<\/tr>\n<tr>\n<td>5Y<\/td>\n<td>Data not available<\/td>\n<td>Data not available<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The one-month picture is modest, but the fund still held a small gain while the benchmark slipped. The three-month stretch is much stronger, with a double-digit fund return versus a negative benchmark return. That tells us the fund has recently benefited from a clear sector-specific recovery even though the broader market benchmark stayed weak.<\/p>\n<p>Over 1 year, the fund\u2019s 20.48% return stands well above the benchmark\u2019s -8.27%. That gap is large enough to show meaningful outperformance over the period, but it also reflects the fund\u2019s sector focus rather than broad-market participation. For investors, that matters because healthcare-oriented performance can diverge sharply from a general index.<\/p>\n<p>The daily path over the recent periods also suggests a choppy but improving trend rather than a smooth climb. There were small pullbacks along the way, yet the recovery later in the period was more persistent. Because the fund launched only in late 2024, there is not yet a full long-term cycle here, so the recent strength should be read as encouraging but still early in the scheme\u2019s life.<\/p>\n<p class=\"mf-source-date\"><small>Source data date: as of 15 Sep 2026<\/small><\/p>\n<section class=\"univest-mf-premium-cta\" style=\"margin:28px 0;padding:24px;border-radius:10px;border:1px solid #d8e3f0;background:#f7faff\">\n<h2 style=\"font-weight:700\"><span class=\"ez-toc-section\" id=\"Should_you_BUY_or_HOLD_Bajaj_Finserv_Healthcare\"><\/span>Should you BUY or HOLD Bajaj Finserv Healthcare?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>A fund&#8217;s past returns alone don&#8217;t tell you whether you should buy it today or continue holding it.<\/p>\n<p>The right decision depends on factors such as your current allocation, purchase price, risk profile, investment horizon and the role this fund plays in your overall portfolio.<\/p>\n<p><strong>Already holding Bajaj Finserv Healthcare? Thinking of investing now?<\/strong><\/p>\n<p><a href=\"https:\/\/univest.in\/mutual-funds\" style=\"font-weight:700;text-decoration:none\">Get your portfolio analysed for FREE by SEBI-registered Investment Adviser (RIA) through Univest MF Premium<\/a><\/p>\n<\/section>\n<h2 style=\"font-weight:700\"><span class=\"ez-toc-section\" id=\"Peer_comparison\"><\/span>Peer comparison<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Fund<\/th>\n<th>1Y return<\/th>\n<th>3Y return<\/th>\n<th>5Y return<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><a href=\"https:\/\/univest.in\/mutual-funds\/bajaj-finserv-healthcare-fund-g-direct-plan\">Bajaj Finserv Healthcare Fund Direct Growth Plan<\/a><\/td>\n<td>20.48%<\/td>\n<td>Data not available<\/td>\n<td>Data not available<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/univest.in\/mutual-funds\/icici-pru-strategic-metal-and-energy-equity-fof-g-direct-plan\">ICICI Pru Strategic Metal and Energy Equity FoF Direct Growth Plan<\/a><\/td>\n<td>69.16%<\/td>\n<td>37.12%<\/td>\n<td>Data not available<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/univest.in\/mutual-funds\/hdfc-pharma-and-healthcare-fund-g-direct-plan\">HDFC Pharma and Healthcare Fund Direct Growth Plan<\/a><\/td>\n<td>27.47%<\/td>\n<td>Data not available<\/td>\n<td>Data not available<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/univest.in\/mutual-funds\/sbi-automotive-opportunities-fund-g-direct-plan\">SBI Automotive Opportunities Fund Direct Growth Plan<\/a><\/td>\n<td>27.05%<\/td>\n<td>Data not available<\/td>\n<td>Data not available<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/univest.in\/mutual-funds\/kotak-healthcare-fund-g-direct-plan\">Kotak Healthcare Fund Direct Growth Plan<\/a><\/td>\n<td>26.51%<\/td>\n<td>Data not available<\/td>\n<td>Data not available<\/td>\n<\/tr>\n<tr>\n<td><a href=\"https:\/\/univest.in\/mutual-funds\/motilal-oswal-active-momentum-fund-g-direct-plan\">Motilal Oswal Active Momentum Fund Direct Growth Plan<\/a><\/td>\n<td>25.46%<\/td>\n<td>Data not available<\/td>\n<td>Data not available<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>This assessment is prepared by Uniapps Investment Adviser Pvt. Ltd. under SEBI Registered Investment Adviser registration INA000017639. On the 1-year view, this fund trails several of the listed comparables, especially the stronger sector- and theme-oriented peers that have posted higher gains. The short-term comparison therefore looks mixed: the fund is positive, but not as strong as the best available peer returns.<\/p>\n<p>On the longer-horizon columns, most peers in the list do not yet have usable 3-year or 5-year figures, so the comparison is incomplete. The only peer with a 3-year figure is the metal-and-energy FoF, which has been far stronger on that measure. That said, the available peer set does not tell one single story: the fund\u2019s 1-year showing is respectable, but it does not match the standout one-year numbers at the top of the list.<\/p>\n<p class=\"mf-source-date\"><small>Source data date: as of 15 Sep 2026<\/small><\/p>\n<div class=\"univest-peer-login-cta\" style=\"margin:20px 0;padding:16px 18px;border:1px solid #d8e3f0;border-radius:8px;background:#f7faff\">\n<p style=\"margin:0\"><strong>Want to know more?<\/strong> <a href=\"https:\/\/univest.in\/user\/log-in\" style=\"font-weight:700;text-decoration:none\">Log in to Univest<\/a> for more mutual fund insights.<\/p>\n<\/div>\n<h2 style=\"font-weight:700\"><span class=\"ez-toc-section\" id=\"Portfolio_where_your_money_goes\"><\/span>Portfolio: where your money goes<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Holding<\/th>\n<th>Sector<\/th>\n<th>Weight<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Divi&#8217;S Laboratories Limited<\/td>\n<td>Healthcare<\/td>\n<td>10.55%<\/td>\n<\/tr>\n<tr>\n<td>Sun Pharmaceutical Industries Limited<\/td>\n<td>Healthcare<\/td>\n<td>8.21%<\/td>\n<\/tr>\n<tr>\n<td>Rubicon Research Limited<\/td>\n<td>Domestic Equities<\/td>\n<td>6.81%<\/td>\n<\/tr>\n<tr>\n<td>Piramal Pharma Limited<\/td>\n<td>Healthcare<\/td>\n<td>6.72%<\/td>\n<\/tr>\n<tr>\n<td>Aurobindo Pharma Limited<\/td>\n<td>Healthcare<\/td>\n<td>6.18%<\/td>\n<\/tr>\n<tr>\n<td>Apollo Hospitals Enterprise Limited<\/td>\n<td>Healthcare<\/td>\n<td>6%<\/td>\n<\/tr>\n<tr>\n<td>Torrent Pharmaceuticals Limited<\/td>\n<td>Healthcare<\/td>\n<td>5.03%<\/td>\n<\/tr>\n<tr>\n<td>Neuland Laboratories Limited<\/td>\n<td>Healthcare<\/td>\n<td>4.11%<\/td>\n<\/tr>\n<tr>\n<td>Emcure Pharmaceuticals Limited<\/td>\n<td>Healthcare<\/td>\n<td>3.84%<\/td>\n<\/tr>\n<tr>\n<td>Max Healthcare Institute Limited<\/td>\n<td>Healthcare<\/td>\n<td>3.35%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The largest holding, Divi&#39;S Laboratories Limited, is 10.55%, which is large enough to matter on its own, but not so large that one stock dominates the entire portfolio. The fall from the first holding to the tenth is gradual rather than abrupt, moving from double-digit weight into the low-single-digit range. That pattern suggests the fund uses a core of meaningful positions rather than relying on a single outsized bet.<\/p>\n<p>The top 10 holdings together account for approximately 60.8% of the portfolio, and the fund has 34 disclosed holdings in total. That combination points to a portfolio that is fairly concentrated at the top while still retaining a longer tail of smaller positions. In practice, the larger healthcare names are likely to have greater influence on returns, while the smaller holdings may add diversification but with less impact on day-to-day performance.<\/p>\n<p>Because most of the listed holdings are in healthcare, the portfolio remains tightly linked to sector trends. Rubicon Research Limited is the only top-10 holding labelled outside healthcare, which reinforces the fund\u2019s sector focus and means performance may move differently from a broad market fund.<\/p>\n<p>To see all holdings, visit the <a href=\"https:\/\/univest.in\/mutual-funds\/bajaj-finserv-healthcare-fund-g-direct-plan\">Bajaj Finserv Healthcare Fund Direct Growth Plan<\/a> page<\/p>\n<p class=\"mf-source-date\"><small>Source data date: as of 15 Sep 2026<\/small><\/p>\n<h2 style=\"font-weight:700\"><span class=\"ez-toc-section\" id=\"Who_should_invest\"><\/span>Who should invest<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>This fund may suit investors who can tolerate High Risk and are comfortable with healthcare-sector swings. Its recent return pattern is encouraging, but the absence of a longer live track record means the fund is still building its history.<\/p>\n<p>It is better viewed with a medium-to-long horizon, because sector-focused funds can move sharply over shorter periods and may not track the broad market closely. Investors who want steady, benchmark-like behaviour may find the divergence uncomfortable, while those seeking targeted healthcare exposure may see the trade-off as acceptable.<\/p>\n<h2 style=\"font-weight:700\"><span class=\"ez-toc-section\" id=\"Tax_and_exit_load\"><\/span>Tax and exit load<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Holding period<\/th>\n<th>Tax rate<\/th>\n<th>Description<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Units held less than 1 year<\/td>\n<td>20%<\/td>\n<td>Short-term capital gains tax<\/td>\n<\/tr>\n<tr>\n<td>Units held more than 1 year<\/td>\n<td>12.5%<\/td>\n<td>Long-term capital gains tax<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Exit load applies at 1% if units are sold within 3 months, and it is nil after 3 months.<\/p>\n<p class=\"mf-source-date\"><small>Source data date: as of 15 Sep 2026<\/small><\/p>\n<h2 style=\"font-weight:700\"><span class=\"ez-toc-section\" id=\"Frequently_asked_questions\"><\/span>Frequently asked questions<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3 style=\"font-weight:700\"><span class=\"ez-toc-section\" id=\"What_is_the_current_NAV_of_Bajaj_Finserv_Healthcare_Fund_Direct_Growth_Plan\"><\/span>What is the current NAV of Bajaj Finserv Healthcare Fund Direct Growth Plan?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The current NAV is \u20b912.084 as of 15 Sep 2026.<\/p>\n<h3 style=\"font-weight:700\"><span class=\"ez-toc-section\" id=\"What_are_the_funds_1-year_3-year_and_5-year_returns\"><\/span>What are the fund\u2019s 1-year, 3-year and 5-year returns?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The fund\u2019s 1-year return is 20.48%. Its 3-year and 5-year returns are not available because the scheme is too new for those periods.<\/p>\n<h3 style=\"font-weight:700\"><span class=\"ez-toc-section\" id=\"How_has_the_fund_performed_against_the_benchmark\"><\/span>How has the fund performed against the benchmark?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>It has outperformed the Nifty 50 over the available time frames. The fund shows 0.22% over 1 month, 12.68% over 3 months and 20.48% over 1 year, while the benchmark is negative across those same periods.<\/p>\n<h3 style=\"font-weight:700\"><span class=\"ez-toc-section\" id=\"How_does_it_compare_with_the_listed_peer_funds\"><\/span>How does it compare with the listed peer funds?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The fund\u2019s 1-year return is lower than several of the listed peers, including HDFC Pharma and Healthcare Fund Direct Growth Plan at 27.47% and Kotak Healthcare Fund Direct Growth Plan at 26.51%. The peer set has limited usable 3-year and 5-year data, so longer-horizon comparison is incomplete.<\/p>\n<h3 style=\"font-weight:700\"><span class=\"ez-toc-section\" id=\"Is_there_a_minimum_SIP_amount\"><\/span>Is there a minimum SIP amount?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The minimum SIP amount is \u20b9500.<\/p>\n<h3 style=\"font-weight:700\"><span class=\"ez-toc-section\" id=\"What_are_the_risk_profile_portfolio_style_and_exit_load\"><\/span>What are the risk profile, portfolio style and exit load?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The fund is marked High Risk and its top holdings are led by healthcare names such as Divi&#39;S Laboratories Limited, Sun Pharmaceutical Industries Limited and Piramal Pharma Limited. Exit load is 1% if units are sold within 3 months, and nil after 3 months.<\/p>\n<h2 style=\"font-weight:700\"><span class=\"ez-toc-section\" id=\"Bottom_line\"><\/span>Bottom line<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Bajaj Finserv Healthcare Fund Direct Growth Plan has delivered a strong recent showing, but its short history means the longer-term picture is still incomplete. The available peer comparison is mixed: several comparable themes have stronger 1-year numbers, while the peer set offers little usable long-horizon evidence for most funds. The portfolio is heavily tilted toward healthcare stocks, so the fund may appeal to investors who want focused sector exposure and can live with High Risk behaviour rather than broad-market steadiness.<\/p>\n<p class=\"univest-posted-at\" style=\"font-size:14px;color:#666;margin:20px 0 8px\">Published on 16 September 2026 at 9:07 AM IST<\/p>\n<section class=\"univest-login-cta\" style=\"margin:28px 0;padding:24px;border-radius:10px;background:#eef5ff;border:1px solid #cddff7;text-align:center\">\n<h2 style=\"font-weight:700\"><span class=\"ez-toc-section\" id=\"Explore_mutual_funds_with_Univest\"><\/span>Explore mutual funds with Univest<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Review mutual fund data, compare performance and explore fund insights on Univest.<\/p>\n<p><a href=\"https:\/\/univest.in\/user\/log-in\" style=\"display:inline-block;padding:11px 20px;border-radius:6px;background:#1f4e79;color:#fff !important;text-decoration:none;font-weight:700\">Explore Univest<\/a><\/p>\n<\/section>\n<section class=\"univest-disclaimer\">\n<h2 style=\"font-weight:700\"><span class=\"ez-toc-section\" id=\"RIA_disclosure\"><\/span>RIA disclosure<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Mutual fund investments are subject to market risks. Read all scheme-related documents carefully before investing. This review is prepared by Uniapps Investment Adviser Pvt. Ltd. (earlier known as Uniapps Global Research Pvt. Ltd.) under SEBI Registered Investment Adviser registration INA000017639 for general informational purposes and is not personalized investment advice.<\/p>\n<\/section>\n<p><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"InvestmentFund\",\"name\":\"Bajaj Finserv Healthcare Fund Direct Growth Plan\",\"identifier\":\"bajaj-finserv-healthcare-fund-g-direct-plan\",\"category\":\"Equity\",\"dateCreated\":\"27 Dec 2024\",\"isAccessibleForFree\":true,\"additionalProperty\":[{\"@type\":\"PropertyValue\",\"name\":\"NAV\",\"value\":12.084,\"valueReference\":\"as of 15 Sep 2026\"},{\"@type\":\"PropertyValue\",\"name\":\"AUM\",\"value\":\"405 Cr\"},{\"@type\":\"PropertyValue\",\"name\":\"Expense Ratio\",\"value\":\"0.72\"},{\"@type\":\"PropertyValue\",\"name\":\"Benchmark\",\"value\":\"Nifty 50\"},{\"@type\":\"PropertyValue\",\"name\":\"1Y Return\",\"value\":20.48},{\"@type\":\"PropertyValue\",\"name\":\"3Y Return\",\"value\":0},{\"@type\":\"PropertyValue\",\"name\":\"5Y Return\",\"value\":0},{\"@type\":\"PropertyValue\",\"name\":\"Fund Managers\",\"value\":\"Vinay Bafna, Bharat Hegde, Siddharth Chaudhary\"}]}<\/script><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is the current NAV of Bajaj Finserv Healthcare Fund Direct Growth Plan?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The current NAV is \u20b912.084 as of 15 Sep 2026.\"}},{\"@type\":\"Question\",\"name\":\"What are the fund\u2019s 1-year, 3-year and 5-year returns?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The fund\u2019s 1-year return is 20.48%. Its 3-year and 5-year returns are not available because the scheme is too new for those periods.\"}},{\"@type\":\"Question\",\"name\":\"How has the fund performed against the benchmark?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"It has outperformed the Nifty 50 over the available time frames. The fund shows 0.22% over 1 month, 12.68% over 3 months and 20.48% over 1 year, while the benchmark is negative across those same periods.\"}},{\"@type\":\"Question\",\"name\":\"How does it compare with the listed peer funds?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The fund\u2019s 1-year return is lower than several of the listed peers, including HDFC Pharma and Healthcare Fund Direct Growth Plan at 27.47% and Kotak Healthcare Fund Direct Growth Plan at 26.51%. The peer set has limited usable 3-year and 5-year data, so longer-horizon comparison is incomplete.\"}},{\"@type\":\"Question\",\"name\":\"Is there a minimum SIP amount?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The minimum SIP amount is \u20b9500.\"}},{\"@type\":\"Question\",\"name\":\"What are the risk profile, portfolio style and exit load?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The fund is marked High Risk and its top holdings are led by healthcare names such as Divi&#39;S Laboratories Limited, Sun Pharmaceutical Industries Limited and Piramal Pharma Limited. Exit load is 1% if units are sold within 3 months, and nil after 3 months.\"}}]}<\/script><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"Organization\",\"name\":\"Uniapps Investment Adviser Pvt. Ltd.\",\"description\":\"SEBI Registered Investment Adviser INA000017639\"}<\/script><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bajaj Finserv Healthcare Fund Direct Growth Plan has a NAV of \u20b912.084 as of 15 Sep 2026, an AUM of \u20b9405 Cr, and a 1-year return of 20.48%.<\/p>\n","protected":false},"author":38,"featured_media":247723,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3841],"tags":[],"class_list":["post-224790","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-mutual-funds"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["247723"],"rank_math_title":["Bajaj Finserv Healthcare Fund Direct Growth Review 2026"],"rank_math_description":["Bajaj Finserv Healthcare Fund Direct Growth Plan NAV is \u20b912.084 as of 15 Sep 2026; 1-year return is 20.48%."],"rank_math_focus_keyword":["Bajaj Finserv Healthcare Fund Direct Growth Plan review"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/09\/Bajaj_Finserv_Healthcare_Fund_Direct_Growth_Review_2026_NAV_Returns_Portfolio_Should_You_Invest_bullish.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/224790","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=224790"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/224790\/revisions"}],"predecessor-version":[{"id":247724,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/224790\/revisions\/247724"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/247723"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=224790"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=224790"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=224790"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}